We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

170 hedge funds and large institutions have $398M invested in Allogene Therapeutics in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 22

10% more funds holding

Funds holding: 154 → 170 (+16)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less capital invested

Capital invested by funds: $413M → $398M (-$15.5M)

4% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 52

4.09% less ownership

Funds ownership: 77.73% → 73.64% (-4.1%)

79% less call options, than puts

Call options by funds: $96K | Put options by funds: $451K

Holders
170
Holders Change
+16
Holders Change %
+10.39%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
39
Increased
50
Reduced
52
Closed
22
Calls
$96K
Puts
$451K
Net Calls
-$355K
Net Calls Change
-$81K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.54M
2
Goldman Sachs
Goldman Sachs
New York
+$5.47M
3
Millennium Management
Millennium Management
New York
+$5.09M
4
BlackRock
BlackRock
New York
+$3.14M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$16.4M
2
EC
EcoR1 Capital
California
-$14.2M
3
WP
Woodline Partners
California
-$7.76M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$4.42M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
176
Squarepoint
New York
– -$386K -121,792 Closed
Tudor Investment Corp
177
Tudor Investment Corp
Connecticut
– -$235K -73,998 Closed
KWM
178
Keebeck Wealth Management
Illinois
– -$146K -46,000 Closed
EFM
179
E Fund Management
China
– -$128K -40,325 Closed
PCM
180
Penserra Capital Management
California
– -$89K -28,284 Closed
MAM
181
Martingale Asset Management
Massachusetts
– -$87.3K -27,526 Closed
BCM
182
Bayesian Capital Management
New York
– -$84K -26,500 Closed
Franklin Resources
183
Franklin Resources
California
– -$78.8K -24,853 Closed
CI Investments Inc
184
CI Investments Inc
Ontario, Canada
– -$47K -14,936 Closed
CC
185
Corton Capital
Ontario, Canada
– -$40K -12,628 Closed
DWT
186
Dorsey & Whitney Trust
South Dakota
– -$38.9K -12,265 Closed
GS
187
GTS Securities
New York
– -$34.9K -10,994 Closed
VanEck Associates
188
VanEck Associates
New York
– -$7K -2,337 Closed
CG
189
Cutler Group
California
– -$4K -1,360 Closed
C
190
Covestor
United Kingdom
– -$6 -2 -9%
4 5 6 7
8

ALLO Hedge Fund Activity: Q4 2023 in Review

170 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2023, worth a combined $398M — down 3.8% from $413M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ALLO positions and 22 closed out — a net gain of 17 holders — while 50 added to existing stakes and 52 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.54M. The largest seller was State Street, cutting an estimated $16.4M.

  • 170 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2023, up from 154 in Q3 2023.
  • Funds reported $398M of Allogene Therapeutics stock for Q4 2023, down 3.8% quarter-over-quarter.
  • 39 funds opened new Allogene Therapeutics positions in Q4 2023 and 22 closed out, a net change of +17 holders.
  • The largest Allogene Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $5.54M added.
  • The largest Allogene Therapeutics seller in Q4 2023 was State Street, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2023.